8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 6, 2016

Aceto Corporation

(Exact Name of Registrant as Specified in its Charter)

New York	000-04217	11-1720520
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4 Tri Harbor Court, Port Washington, NY 11050

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (516) 627-6000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13-e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

The Board of Directors (the “Board”) of Aceto Corporation (the “Company”) appointed William C. Kennally, III as a member of the Board. The appointment is effective September 6, 2016. Mr. Kennally is expected to stand for election with the other directors at the Company’s Annual Meeting of shareholders scheduled in December 2016. As of the date of this report, Mr. Kennally has not been named to any committee of the Board. Mr. Kennally was not selected as a director pursuant to any arrangement or understanding with any other person, and does not have any reportable transactions under Item 404(a) of Regulation S-K.

For his services as a director of the Company, it is contemplated that Mr. Kennally will receive the Company’s standard compensation applicable to nonemployee directors.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits
Exhibit No.	Description
99.1	Press Release, dated September 6, 2016

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ACETO CORPORATION
Dated: September 9, 2016	By: /s/ Salvatore Guccione
	Salvatore Guccione
	President and CEO

3

EX-99.1

Exhibit 99.1

ACETO Corporation

4 Tri Harbor Court

Port Washington, New York 11050

“Sourcing and Supplying Quality Products Worldwide” NEWS RELEASE

 FOR IMMEDIATE RELEASE

ACETO Appoints William C. Kennally, III to the Board of Directors

PORT WASHINGTON, N.Y., September 6, 2016 -- ACETO Corporation (Nasdaq: ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced that it has appointed William C. Kennally, III, 61 years old, to its Board of Directors, effective September 6, 2016.

Chairman of the Board, Albert Eilender, commented, “We are pleased to welcome Bill to the ACETO board.  He has deep, multi-faceted experience in pharmaceutical sales, general management, and business leadership gained over a 37-year distinguished career.  We look forward to drawing on Bill’s vast experience and industry knowledge in the pharmaceutical arena.”

Mr. Kennally started his career in pharmaceutical sales in 1979 with The Upjohn Company which was later acquired by Pharmacia. During his career, Bill held positions of increasing responsibility within Pfizer and Pharmacia including President, Greenstone, LLC, a generic and authorized generic pharmaceuticals supplier which became a wholly-owned subsidiary of Pfizer, Inc. after Pfizer’s acquisition of Pharmacia. In 2010, Bill became Regional President North America, Global Established Products for Pfizer, and prior to his retirement in 2015 was Regional President North America Advisor, Global Established Pharma with Pfizer.

About ACETO

ACETO Corporation, incorporated in 1947 and with offices and operations in 10 countries, is engaged in the development, marketing, sale and distribution of Human Health products (finished dosage form generics and nutraceuticals), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products).

Investor Relations Contact:
LHA
Jody Burfening
jburfening@lhai.com

(212) 838-3777